ArticleWorld journal of gastrointestinal oncology2025
Colorectal follicular lymphoma: A single-center retrospective study.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe concept of "duodenal-type follicular lymphoma (FL)" has already been established as a disease entity. On the other hand, because FL that develops in the colorectum is a rare disease, its clinical characteristics, including its treatment and outcome, are poorly understood.
aimTo clarify the characteristic clinical features of colorectal FL.
methodsWe identified 5 patients with FL from December 2010 to July 2022 whose colorectal lesions were confirmed by endoscopic biopsy at our hospital and retrospectively examined their clinical features, including endoscopic findings, treatment, and long-term outcomes.
resultsThe median age of the patients was 70 years (range 62-74 years, 3 males and 2 females), and 2 patients were considered to have systemic FL lesions. Endoscopic findings revealed elavated lesions in all 5 patients (polypoid 3, flat elavated 1, papular 1). Only 1 patient underwent therapeutic intervention, and 4 patients chose watchful waiting. Except for 1 patient in which the lesion spontaneously regressed, the disease recurred or progressed in 4 patients, 3 of whom eventually achieved near complete remission with the administration of rituximab and bendamustine (± polatuzumab vedotin). The 5 patients in this study were still alive or exhibited long-term survival before death; the survival time ranged from 8-29 years after the onset of lymphoma.
conclusionIn the present study, colorectal FL progressed slowly, and overall survival was good because it was sensitive to anticancer drugs even after the disease progressed without initial therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.